Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.37 |
| ▸ | F2R | P25116 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14573991 | 0.93 | ITGB3 (0.39) | ITGB3ITGA2BCTSSCTSKACE | |
| SCHEMBL5155647 | 0.89 | ITGB3 (0.44) | ITGB3ITGA2BCTSSCTSKTSHR | |
| SCHEMBL5151071 | 0.83 | ITGB3 (0.46) | ITGB3ITGA2BCTSSCTSKTSHR | |
| SCHEMBL14573987 | 0.82 | ITGB3 (0.38) | ITGB3ITGA2BCTSSCTSKTSHR | |
| SCHEMBL5151111 | 0.79 | ITGB3 (0.41) | ITGB3ITGA2BCTSSCTSKACE | |
| SCHEMBL21409319 | 0.79 | CTSK (0.44) | ITGB3ITGA2BCTSSCTSKACE | |
| SCHEMBL21409318 | 0.79 | CTSK (0.44) | ITGB3ITGA2BCTSSCTSKACE | |
| SCHEMBL3892487 | 0.78 | CTSK (0.45) | ITGB3ITGA2BCTSSCTSKTSHR | |
| SCHEMBL3892481 | 0.78 | CTSK (0.45) | ITGB3ITGA2BCTSSCTSKTSHR | |
| SCHEMBL5151021 | 0.78 | MEN1 (0.41) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1673384-A4 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1673384-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030135-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | GLS, NOS2, NOS1 | ITGB3 2069/4885ITGA2B 2429/4885CTSS 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.